Developer docs
API playgroundTry for free, no card

Search company profiles

Diasome Pharmaceuticals

Full company profile

uuid0002ikc

Namestring
Diasome Pharmaceuticals
Legal namestring
Diasome Pharmaceuticals, Inc.
Websiteurl
diasome.com
Company typeenum
Private
Founded yearint
2012
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diabetes therapeutics, hepatocyte-directed vesicle platform, insulin drug delivery, liver-targeted therapies, metabolic disease drugs
Industry2 codes
PRIMARYHLAHAIAC
Pen Injectors (Insulin/GLP-1/Other Pens)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Diabetes Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Once approved, Diasome will generate revenue through sales of HDV-formulated drugs, primarily HDV-Insulin Lispro for Type 1 and Type 2 diabetes. The company is also developing HDV-GLP-1 and HDV-Serotonin programs.

diasome.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Diasome Pharmaceuticals develops clinical-stage insulin-based and metabolic therapies using its proprietary HDV (Hepatocyte-Directed Vesicle) platform, which preferentially delivers drug actives to hepatocyte receptors in the portal-hepatic region. The company's lead product, HDV-Insulin Lispro, combines the HDV platform with insulin lispro to restore physiologic hepatic insulin exposure, while additional programs HDV-GLP-1 and HDV-Serotonin extend the platform to incretin therapy and hepatic insulin resistance respectively.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • A1C non-inferiority maintained at Weeks 12 (0.08% difference) and 25 (0.07% difference) meeting FDA's <0.1% threshold
+4 more records
Product overview1 text field

Diasome Pharmaceuticals is advancing a new class of liver-targeted medicines through its proprietary HDV™ (Hepatocyte-Directed Vesicle) platform. The HDV platform is a first-in-class phospholipid bilayer bicelle technology that delivers therapeutic actives preferentially to hepatocytes in the portal-hepatic region, restoring liver-driven metabolic control. The company's product portfolio consists of three clinical programs: HDV-Insulin Lispro (lead program in Phase 2b for Type 1 diabetes, targeting hypoglycemia reduction), HDV-GLP-1 (preclinical/Phase 1 for Type 2 diabetes targeting the gut-liver-brain axis), and HDV-Serotonin (preclinical oral therapy for insulin resistance). Diasome's approach transforms familiar drug molecules into first-in-class, liver-directed therapies by leveraging the HDV platform's ability to bind and deliver active pharmaceutical ingredients to the liver.

Product and service4 records
1HDV (Hepatocyte-Directed Vesicle) Platform
CategoryDrug Delivery Platform Technology
Description

Proprietary drug delivery platform using a phospholipid bilayer bicelle with Biotin-PE surface targeting to deliver therapeutic actives preferentially to hepatocyte receptors via the SMVT transporter in the portal-hepatic region. The platform binds up to 100 proteins and peptides per disc and is compatible with insulin, GLP-1, and serotonin, supporting both injectable and oral formulations.

2HDV-Insulin Lispro
CategoryDiabetes Therapeutics
Description

Lead clinical-stage product combining the HDV platform with insulin lispro to restore physiologic liver insulin exposure in patients with Type 1 diabetes. OPTI-2 Phase 2b trial demonstrated A1C non-inferiority (<0.1% margin met at Weeks 12 and 25) with 24-36% statistically significant reductions in hypoglycemia events and zero Level 3 severe hypoglycemic events versus five with standard insulin lispro.

3HDV-GLP-1
CategoryMetabolic Disease Therapeutics
Description

Pipeline product applying the HDV platform to GLP-1 therapy to target the portal vein and access the gut-liver-brain axis, with the goal of improving efficacy in fat, glucose, and weight endpoints while mitigating off-target side effects. Currently in preclinical/Phase 1 stage for Type 2 diabetes.

4HDV-Serotonin
CategoryMetabolic Disease Therapeutics
Description

First-in-class oral therapy designed to replace declining or deficient portal-hepatic serotonin levels, enabling hepatic utilization of insulin and addressing hepatic and peripheral insulin resistance in Type 2 diabetes. Currently in preclinical stage.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

UNC School of Medicine researchers collaborated with Diasome on the OPTI-2 Phase 2b clinical trial. Dr. Klara Klein, MD, PhD, Assistant Professor of Medicine, served as principal investigator presenting results at ADA 86th Scientific Sessions.

Strategic tierSupportingTypeTechnology or Integration
Description

Diasome's OPTI-2 trial utilized Dexcom G7 Continuous Glucose Monitoring system throughout the 25-week treatment period for dose optimization and hypoglycemia assessment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Danish clinical-stage biotech developing peptide therapeutics for metabolic disease, including a dasiglucagon hypoglycemia rescue program and GLP-1/GLP-2 assets. Comparable as a small-cap European peptide-focused company overlapping with Diasome's HDV-GLP-1 and HDV-Serotonin efforts.

TypeDirect peer
Description

French clinical-stage biotech developing Imeglimin (Twymeeg) and other mitochondrial-targeted therapies for Type 2 diabetes and metabolic disease. Comparable as a small-cap European clinical-stage company targeting hepatic/mitochondrial mechanisms to address insulin resistance and glycemic control.

TypeDirect peer
Description

Clinical-stage biotech focused on small-molecule therapies for metabolic disease, including Type 1 diabetes (TTP399) and renal/cardiac indications. Comparable as a small-cap, clinical-stage company pursuing differentiated mechanisms in diabetes and cardiometabolic disease.

TypeEmerging player
Description

Clinical-stage biotech developing DM199 (klotho) for chronic kidney disease, diabetes, and stroke. Comparable as a small clinical-stage company advancing peptide-based therapies into metabolic disease indications overlapping with Diasome's HDV-enabled programs.

TypeDirect peer
Description

French clinical-stage biotech developing reformulated insulin and GLP-1 formulations using BioChaperone delivery technology. Closest direct peer to Diasome given parallel approach of enhancing insulin pharmacology through novel formulation/delivery for diabetes and metabolic indications.

TypeDirect peer
Description

Clinical-stage biotech with a diabetes-focused pipeline (sotagliflozin / Zynquista) and broader cardiometabolic assets. Comparable as a small-cap clinical-stage company pursuing differentiated mechanisms in Type 1 and Type 2 diabetes.

TypeDirect peer
Description

Commercial-stage company with Afrezza (inhaled insulin) and a pipeline of endocrine/metabolic therapies. Highly comparable as a small, diabetes-focused company delivering established insulin molecules via a differentiated delivery technology to address unmet needs in mealtime glucose control.

TypeBroad incumbent
Description

One of two global leaders in insulin (Humalog, Lyumjev) and GLP-1 (Trulicity, Mounjaro, Zepbound). Broad incumbent operating across the same diabetes/obesity indications Diasome is targeting; also an investor/strategic partner in Diasome's Series C.

TypeBroad incumbent
Description

World leader in insulin (NovoLog, Fiasp) and GLP-1 (Ozempic, Wegovy). Broad incumbent across Diasome's core therapeutic categories — Type 1 and Type 2 diabetes, obesity — and a benchmark for any future commercial-scale liver-targeted insulin or GLP-1 launch.

TypeDirect peer
Description

Clinical-stage biotech developing oral insulin (ORMD-0801) and an oral GLP-1 (ORMD-0901). Comparable as a small-cap, clinical-stage diabetes company reformulating established peptide drugs (insulin, GLP-1) for improved delivery — directly analogous to Diasome's HDV-Insulin and HDV-GLP-1 strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Diasome Pharmaceuticals

Diabetes Therapeuticsdiasome.com

Diasome Pharmaceuticals firmographics

Firmographics
Name
Diasome Pharmaceuticals
Legal name
Diasome Pharmaceuticals, Inc.
Website
https://diasome.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Diasome Pharmaceuticals industry classification

Industry
Product category
Diabetes Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAIAC
Pen Injectors (Insulin/GLP-1/Other Pens)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAHAJ
Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Diabetes therapeutics
  • Hepatocyte-directed vesicle platform
  • Insulin drug delivery
  • Liver-targeted therapies
  • Metabolic disease drugs

Where Diasome Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Diasome Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Once approved, Diasome will generate revenue through sales of HDV-formulated drugs, primarily HDV-Insulin Lispro for Type 1 and Type 2 diabetes. The company is also developing HDV-GLP-1 and HDV-Serotonin programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Diasome Pharmaceuticals product offering

Product offering

Core offering

Diasome Pharmaceuticals develops clinical-stage insulin-based and metabolic therapies using its proprietary HDV (Hepatocyte-Directed Vesicle) platform, which preferentially delivers drug actives to hepatocyte receptors in the portal-hepatic region. The company's lead product, HDV-Insulin Lispro, combines the HDV platform with insulin lispro to restore physiologic hepatic insulin exposure, while additional programs HDV-GLP-1 and HDV-Serotonin extend the platform to incretin therapy and hepatic insulin resistance respectively.

Product overview

Diasome Pharmaceuticals is advancing a new class of liver-targeted medicines through its proprietary HDV™ (Hepatocyte-Directed Vesicle) platform. The HDV platform is a first-in-class phospholipid bilayer bicelle technology that delivers therapeutic actives preferentially to hepatocytes in the portal-hepatic region, restoring liver-driven metabolic control. The company's product portfolio consists of three clinical programs: HDV-Insulin Lispro (lead program in Phase 2b for Type 1 diabetes, targeting hypoglycemia reduction), HDV-GLP-1 (preclinical/Phase 1 for Type 2 diabetes targeting the gut-liver-brain axis), and HDV-Serotonin (preclinical oral therapy for insulin resistance). Diasome's approach transforms familiar drug molecules into first-in-class, liver-directed therapies by leveraging the HDV platform's ability to bind and deliver active pharmaceutical ingredients to the liver.

Differentiator

Problem solved

Functional benefit

Products and services

  • HDV (Hepatocyte-Directed Vesicle) Platform Proprietary drug delivery platform using a phospholipid bilayer bicelle with Biotin-PE surface targeting to deliver therapeutic actives preferentially to hepatocyte receptors via the SMVT transporter in the portal-hepatic region. The platform binds up to 100 proteins and peptides per disc and is compatible with insulin, GLP-1, and serotonin, supporting both injectable and oral formulations.
  • HDV-Insulin Lispro Lead clinical-stage product combining the HDV platform with insulin lispro to restore physiologic liver insulin exposure in patients with Type 1 diabetes. OPTI-2 Phase 2b trial demonstrated A1C non-inferiority (<0.1% margin met at Weeks 12 and 25) with 24-36% statistically significant reductions in hypoglycemia events and zero Level 3 severe hypoglycemic events versus five with standard insulin lispro.
  • HDV-GLP-1 Pipeline product applying the HDV platform to GLP-1 therapy to target the portal vein and access the gut-liver-brain axis, with the goal of improving efficacy in fat, glucose, and weight endpoints while mitigating off-target side effects. Currently in preclinical/Phase 1 stage for Type 2 diabetes.
  • HDV-Serotonin First-in-class oral therapy designed to replace declining or deficient portal-hepatic serotonin levels, enabling hepatic utilization of insulin and addressing hepatic and peripheral insulin resistance in Type 2 diabetes. Currently in preclinical stage.

Quantifiable outcome

  • A1C non-inferiority maintained at Weeks 12 (0.08% difference) and 25 (0.07% difference) meeting FDA's <0.1% threshold
  • +4 more outcomes

Companies that use Diasome Pharmaceuticals

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Diasome Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Diasome Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and supporting.

  • University of North Carolina School of MedicinecoreStrategic or Co-development PartnerUNC School of Medicine researchers collaborated with Diasome on the OPTI-2 Phase 2b clinical trial. Dr. Klara Klein, MD, PhD, Assistant Professor of Medicine, served as principal investigator presenting results at ADA 86th Scientific Sessions.
  • DexcomsupportingTechnology or IntegrationDiasome's OPTI-2 trial utilized Dexcom G7 Continuous Glucose Monitoring system throughout the 25-week treatment period for dose optimization and hypoglycemia assessment.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Diasome Pharmaceuticals competitors and assessment

Company assessment

Emerging players

  • Zealand Pharma: Danish clinical-stage biotech developing peptide therapeutics for metabolic disease, including a dasiglucagon hypoglycemia rescue program and GLP-1/GLP-2 assets. Comparable as a small-cap European peptide-focused company overlapping with Diasome's HDV-GLP-1 and HDV-Serotonin efforts.
  • DiaMedica Therapeutics: Clinical-stage biotech developing DM199 (klotho) for chronic kidney disease, diabetes, and stroke. Comparable as a small clinical-stage company advancing peptide-based therapies into metabolic disease indications overlapping with Diasome's HDV-enabled programs.

Direct peers

  • Poxel SA: French clinical-stage biotech developing Imeglimin (Twymeeg) and other mitochondrial-targeted therapies for Type 2 diabetes and metabolic disease. Comparable as a small-cap European clinical-stage company targeting hepatic/mitochondrial mechanisms to address insulin resistance and glycemic control.
  • vTv Therapeutics: Clinical-stage biotech focused on small-molecule therapies for metabolic disease, including Type 1 diabetes (TTP399) and renal/cardiac indications. Comparable as a small-cap, clinical-stage company pursuing differentiated mechanisms in diabetes and cardiometabolic disease.
  • Adocia: French clinical-stage biotech developing reformulated insulin and GLP-1 formulations using BioChaperone delivery technology. Closest direct peer to Diasome given parallel approach of enhancing insulin pharmacology through novel formulation/delivery for diabetes and metabolic indications.
  • Lexicon Pharmaceuticals: Clinical-stage biotech with a diabetes-focused pipeline (sotagliflozin / Zynquista) and broader cardiometabolic assets. Comparable as a small-cap clinical-stage company pursuing differentiated mechanisms in Type 1 and Type 2 diabetes.
  • MannKind Corporation: Commercial-stage company with Afrezza (inhaled insulin) and a pipeline of endocrine/metabolic therapies. Highly comparable as a small, diabetes-focused company delivering established insulin molecules via a differentiated delivery technology to address unmet needs in mealtime glucose control.
  • Oramed Pharmaceuticals: Clinical-stage biotech developing oral insulin (ORMD-0801) and an oral GLP-1 (ORMD-0901). Comparable as a small-cap, clinical-stage diabetes company reformulating established peptide drugs (insulin, GLP-1) for improved delivery — directly analogous to Diasome's HDV-Insulin and HDV-GLP-1 strategy.

Broad incumbents

  • Eli Lilly and Company: One of two global leaders in insulin (Humalog, Lyumjev) and GLP-1 (Trulicity, Mounjaro, Zepbound). Broad incumbent operating across the same diabetes/obesity indications Diasome is targeting; also an investor/strategic partner in Diasome's Series C.
  • Novo Nordisk: World leader in insulin (NovoLog, Fiasp) and GLP-1 (Ozempic, Wegovy). Broad incumbent across Diasome's core therapeutic categories — Type 1 and Type 2 diabetes, obesity — and a benchmark for any future commercial-scale liver-targeted insulin or GLP-1 launch.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Diasome Pharmaceuticals social profiles

Digital presence

Diasome Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Diasome Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles14 records

Diasome Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Diasome Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diasome Pharmaceuticals

What does Diasome Pharmaceuticals do?

Diasome Pharmaceuticals develops clinical-stage insulin-based and metabolic therapies using its proprietary HDV (Hepatocyte-Directed Vesicle) platform, which preferentially delivers drug actives to hepatocyte receptors in the portal-hepatic region. The company's lead product, HDV-Insulin Lispro, combines the HDV platform with insulin lispro to restore physiologic hepatic insulin exposure, while additional programs HDV-GLP-1 and HDV-Serotonin extend the platform to incretin therapy and hepatic insulin resistance respectively.

Is Diasome Pharmaceuticals a public or private company?

Diasome Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Diasome Pharmaceuticals founded?

Diasome Pharmaceuticals was founded in 2012. It employs 11 to 50 people.

Where is Diasome Pharmaceuticals based?

Diasome Pharmaceuticals is headquartered in Cleveland, United States, in the North America region.

How does Diasome Pharmaceuticals make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Diasome Pharmaceuticals's main competitors?

Emerging players on record are Zealand Pharma and DiaMedica Therapeutics. Direct peers are Poxel SA, vTv Therapeutics, Adocia, Lexicon Pharmaceuticals, MannKind Corporation and Oramed Pharmaceuticals. Broad incumbents are Eli Lilly and Company and Novo Nordisk.

Does Diasome Pharmaceuticals have an API?

No public API is recorded for Diasome Pharmaceuticals.

What industry is Diasome Pharmaceuticals in?

Diasome Pharmaceuticals's product category is Diabetes Therapeutics. Its primary akta.pro industry code is HLAHAIAC, Pen Injectors (Insulin/GLP-1/Other Pens), with a secondary code of HLAHAHAJ, Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GenengnewsDiasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising DataDiasome is finalizing Phase III plans for its hepatocyte-directed insulin lispro (HDV-insulin) after positive Phase IIb data. The trial showed HDV-insulin was non-inferior to standard insulin lispro in reducing A1C and reduced severe hypoglycemia. The company expects to present pivotal data to the FDA soon.EIN PresswireDiasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising DataDiasome is finalizing Phase III plans for its HDV-insulin formulation after positive Phase IIb data showed non-inferior A1C reduction and lower hypoglycemia compared to insulin lispro. The company raised about $85 million and anticipates a Series D financing. It aims to present pivotal data to the FDA soon.BioSpaceDiasome Pharmaceuticals to Present HDV-Insulin Phase 2b Clinical Data at EASD 2026 and Inaugural Breakthrough T1D Clinical & Research CongressDiasome Pharmaceuticals will present Phase 2b OPTI-2 data at EASD 2026 and the inaugural Breakthrough T1D Clinical & Research Congress. The study compared HDV-insulin lispro with standard insulin lispro in adults with type 1 diabetes, showing potential to maintain glycemic control while reducing hypoglycemia. New exposure-adjusted incidence rate analyses will be presented at the Philadelphia congress.The Pharma LetterDiasome reshapes leadership team as HDV-Insulin heads toward Phase IIIDiasome Pharmaceuticals appointed Sangeeta Sawhney as chief medical officer, succeeding Paul Strumph, who will remain senior medical advisor. The move supports advancing its lead candidate HDV-Insulin into Phase III development. Sawhney brings over 20 years of pharma R&D experience, including at Intercept Pharmaceuticals.BioSpaceDiasome Pharmaceuticals Strengthens Leadership Team as Company Prepares for Phase 3 DevelopmentDiasome Pharmaceuticals appointed Sangeeta Sawhney as Chief Medical Officer and Linda Rubinstein as CFO, with Paul Strumph transitioning to Senior Medical Advisor, as it prepares to advance HDV-Insulin to Phase 3. The company's lead program targets liver-directed insulin therapy for diabetes, with clinical data supporting its potential to decouple glucose control from hypoglycemia risk.Mirage NewsLiver-Targeted Insulin Shows Promise for Type 1 DiabetesUNC School of Medicine researchers, in collaboration with Diasome Pharmaceuticals, have published results from a Phase 2b clinical trial showing that HDV-Lispro, a liver-targeted insulin, maintained equivalent blood glucose control compared to standard insulin while significantly reducing hypoglycemic events in type 1 diabetes patients. The OPTI-2 study found that patients achieved similar A1C targets without severe hypoglycemic episodes, addressing a longstanding challenge in diabetes care where tighter glycemic control typically increases hypoglycemia risk. The researchers indicate larger studies are needed to validate these findings before the treatment could become a clinical option for the approximately 2.1 million Americans living with type 1 diabetes.GlobeNewswireDiasome Presents Phase 2b Data Demonstrating HDV™-Insulin Lispro Maintains Glycemic Control While Reducing Hypoglycemia in Adults with Type 1 DiabetesDiasome Pharmaceuticals presented Phase 2b results from the OPTI-2 trial showing that HDV-Insulin Lispro maintained glycemic control (A1C non-inferiority at weeks 12 and 25) while achieving 24-36% statistically significant reductions in hypoglycemia events compared to standard insulin lispro in 226 adults with type 1 diabetes. Zero severe (Level 3) hypoglycemic events occurred with HDV-LIS versus five in the control group, with the company stating these results support advancing the program into Phase 3 development.DiatribeNew Study Tests Liver-Targeted Insulin in Type 1 DiabetesDiasome Pharmaceuticals, Inc. is conducting a Phase 2b clinical trial (OPTI-2) to evaluate the efficacy of HDV-L insulin, an investigational liver-targeted therapy for type 1 diabetes. The study aims to determine if the drug can reduce severe nighttime hypoglycemic events by 25% or more while maintaining glycemic control compared to standard insulin lispro.American City Business JournalsDiasome Pharmaceuticals could tap $100 billion market for obesity drugsCleveland-based Diasome Pharmaceuticals Inc. announced plans to utilize its nanotechnology to target the $100 billion market for drugs treating Type 2 diabetes and obesity, following a recent Series C funding round that raised $9.5 million. The company intends to invest the new capital in clinical trials for its lead asset, which aims to prevent hypoglycemia in diabetic patients through innovative liver-targeting technology.Crain's Cleveland BusinessCleveland-based Diasome Pharmaceuticals announces $9.5 million first close on Series C financing roundCleveland-based Diasome Pharmaceuticals announced a $9.5 million first close on its Series C financing round. The company, which is an incubator client of Cleveland Clinic Innovations, plans to use the funds to prepare for clinical trials comparing its technology against standard insulin therapy for type 1 diabetes patients.